2.2.0.25truefalse06132 - Disclosure - Reportable Segments (Therapeutic Categories) (Details 2)truefalseIn Millions, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010 USD ($) USD ($) / shares $Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009 USD ($) USD ($) / shares $TwelveMonthsEnded_31Dec2009http://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008 USD ($) USD ($) / shares $TwelveMonthsEnded_31Dec2008http://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalseNet product sales in the therapeutic categories3false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse34159000003415.9falsetruefalsefalsefalse2truefalsefalse26993000002699.3falsetruefalsefalsefalse3truefalsefalse24072000002407.2falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -Paragraph 32 -Subparagraph a truefalseNet product sales, therapeutic categories4true0wpi_ReportableSegmentsTextualsAbstractwpifalsenadurationReportable Segments Textuals Abstract.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringReportable Segments Textuals Abstract.falsefalseReportable Segments (Textuals) [Abstract]5false0wpi_NumberOfReportableSegmentswpifalsenadurationNumber of Reportable Segments.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse33falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:integerItemTypeintegerNumber of Reportable Segments.No authoritative reference available.falsefalseNumber of reportable segments6false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Central nervous system [Member] 1/1/2010 - 12/31/2010 USD ($) $TwelveMonthsEnded_31Dec2010_Central_Nervous_System_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseCentral nervous system [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CentralNervousSystemMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Central nervous system [Member] 1/1/2009 - 12/31/2009 USD ($) $TwelveMonthsEnded_31Dec2009_Central_Nervous_System_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseCentral nervous system [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CentralNervousSystemMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Central nervous system [Member] 1/1/2008 - 12/31/2008 USD ($) $TwelveMonthsEnded_31Dec2008_Central_Nervous_System_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseCentral nervous system [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CentralNervousSystemMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalseCentral nervous system [Member]7true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalseNet product sales in the therapeutic categories8false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse907600000907.6falsefalsefalsefalsefalse2truefalsefalse836700000836.7falsefalsefalsefalsefalse3truefalsefalse795700000795.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -Paragraph 32 -Subparagraph a truefalseNet product sales, therapeutic categories10false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Hormones and synthetic substitutes [Member] 1/1/2010 - 12/31/2010 USD ($) $TwelveMonthsEnded_31Dec2010_Hormones_And_Synthetic_Substitutes_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseHormones and synthetic substitutes [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_HormonesAndSyntheticSubstitutesMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Hormones and synthetic substitutes [Member] 1/1/2009 - 12/31/2009 USD ($) $TwelveMonthsEnded_31Dec2009_Hormones_And_Synthetic_Substitutes_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseHormones and synthetic substitutes [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_HormonesAndSyntheticSubstitutesMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Hormones and synthetic substitutes [Member] 1/1/2008 - 12/31/2008 USD ($) $TwelveMonthsEnded_31Dec2008_Hormones_And_Synthetic_Substitutes_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseHormones and synthetic substitutes [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_HormonesAndSyntheticSubstitutesMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalseHormones and synthetic substitutes [Member]11true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalseNet product sales in the therapeutic categories12false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse682300000682.3falsefalsefalsefalsefalse2truefalsefalse609800000609.8falsefalsefalsefalsefalse3truefalsefalse525700000525.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -Paragraph 32 -Subparagraph a truefalseNet product sales, therapeutic categories14false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse10falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Cardiovascular [Member] 1/1/2010 - 12/31/2010 USD ($) $TwelveMonthsEnded_31Dec2010_Cardiovascular_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseCardiovascular [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CardiovascularMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Cardiovascular [Member] 1/1/2009 - 12/31/2009 USD ($) $TwelveMonthsEnded_31Dec2009_Cardiovascular_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseCardiovascular [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CardiovascularMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Cardiovascular [Member] 1/1/2008 - 12/31/2008 USD ($) $TwelveMonthsEnded_31Dec2008_Cardiovascular_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseCardiovascular [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_CardiovascularMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalseCardiovascular [Member]15true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalseNet product sales in the therapeutic categories16false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse594600000594.6falsefalsefalsefalsefalse2truefalsefalse269400000269.4falsefalsefalsefalsefalse3truefalsefalse245500000245.5falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -Paragraph 32 -Subparagraph a truefalseNet product sales, therapeutic categories18false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse13falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Anti-infective agents [Member] 1/1/2010 - 12/31/2010 USD ($) $TwelveMonthsEnded_31Dec2010_Anti_Infective_Agents_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAnti-infective agents [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AntiInfectiveAgentsMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Anti-infective agents [Member] 1/1/2009 - 12/31/2009 USD ($) $TwelveMonthsEnded_31Dec2009_Anti_Infective_Agents_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAnti-infective agents [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AntiInfectiveAgentsMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$15falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Anti-infective agents [Member] 1/1/2008 - 12/31/2008 USD ($) $TwelveMonthsEnded_31Dec2008_Anti_Infective_Agents_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAnti-infective agents [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_AntiInfectiveAgentsMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalseAnti-infective agents [Member]19true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalseNet product sales in the therapeutic categories20false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse161500000161.5falsefalsefalsefalsefalse2truefalsefalse133700000133.7falsefalsefalsefalsefalse3truefalsefalse116800000116.8falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -Paragraph 32 -Subparagraph a truefalseNet product sales, therapeutic categories22false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse16falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Urology [Member] 1/1/2010 - 12/31/2010 USD ($) $TwelveMonthsEnded_31Dec2010_Urology_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseUrology [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_UrologyMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Urology [Member] 1/1/2009 - 12/31/2009 USD ($) $TwelveMonthsEnded_31Dec2009_Urology_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseUrology [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_UrologyMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$18falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Urology [Member] 1/1/2008 - 12/31/2008 USD ($) $TwelveMonthsEnded_31Dec2008_Urology_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseUrology [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_UrologyMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalseUrology [Member]23true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalseNet product sales in the therapeutic categories24false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse127300000127.3falsefalsefalsefalsefalse2truefalsefalse111400000111.4falsefalsefalsefalsefalse3truefalsefalse8870000088.7falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -Paragraph 32 -Subparagraph a truefalseNet product sales, therapeutic categories26false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://watson.com/role/reportablesegmentsdetails21falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse19falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Others [Member] 1/1/2010 - 12/31/2010 USD ($) $TwelveMonthsEnded_31Dec2010_Others_Memberhttp://www.sec.gov/CIK0000884629duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseOthers [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_OthersMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Others [Member] 1/1/2009 - 12/31/2009 USD ($) $TwelveMonthsEnded_31Dec2009_Others_Memberhttp://www.sec.gov/CIK0000884629duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseOthers [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_OthersMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$21falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Others [Member] 1/1/2008 - 12/31/2008 USD ($) $TwelveMonthsEnded_31Dec2008_Others_Memberhttp://www.sec.gov/CIK0000884629duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseOthers [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldiwpi_OthersMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalseOthers [Member]27true0wpi_NetProductSalesInTherapeuticCategoriesAbstractwpifalsenadurationNet product sales in the therapeutic categories.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNet product sales in the therapeutic categories.falsefalseNet product sales in the therapeutic categories28false0us-gaap_SegmentReportingSegmentRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse942600000942.6falsetruefalsefalsefalse2truefalsefalse738300000738.3falsetruefalsefalsefalse3truefalsefalse634800000634.8falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenues for reportable segments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -Paragraph 32 -Subparagraph a truefalseNet product sales, therapeutic categories322Reportable Segments (Therapeutic Categories) (Details 2) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruetrue